Skip to content

Phase II/III study of MD-712

Phase II/III study of MD-712

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2031240628
Enrollment
15
Registered
2025-01-24
Start date
2025-02-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension and Pulmonary Hypertension associated with Interstitial Lung Disease

Interventions

The initial dose of treprostinil should be set at one 16 mcg per treatment session, 4 times a day. If tolerated, the dose can be gradually increased up to 64 mcg and maintained.

Sponsors

Takahashi Kenta
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient was diagnosed as either idiopathic or heritable PAH, drug- and toxin-induced PAH,CTD-PAH, HIV-PAH, CHD-PAH or PH associated with ILD or CPFE

Exclusion criteria

Exclusion criteria: Patient was diagnosed as PH other than those accepted as outlined in the Inclusion Criteria

Design outcomes

Primary

MeasureTime frame
Rate of change in pulmonary vascular resistance index

Secondary

MeasureTime frame
Amount of change in 6-minute walk distance, etc

Contacts

Public ContactPublic relations

Mochida Pharmaceutical Co., Ltd.

webmaster@mochida.co.jp+81-3-3225-6303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026